Aurinia Pharmaceuticals Inc. (AUPH)
Automate Your Wheel Strategy on AUPH
With Tiblio's Option Bot, you can configure your own wheel strategy including AUPH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AUPH
- Rev/Share 1.7802
- Book/Share 2.5209
- PB 3.4234
- Debt/Equity 0.2225
- CurrentRatio 5.9317
- ROIC 0.0658
- MktCap 1165947520.0
- FreeCF/Share 0.4609
- PFCF 18.2122
- PE 30.0879
- Debt/Assets 0.1543
- DivYield 0
- ROE 0.1077
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Aurinia shares rise ahead of key autoimmune therapy data
Published: June 26, 2025 by: Proactive Investors
Sentiment: Positive
Shares of Aurinia Pharmaceuticals (TSX:AUP)(NASDAQ:AUPH) jumped 6.8% to $8.57 on Thursday afternoon as investors looked ahead to the company's first clinical data update for its experimental autoimmune drug AUR200, which Jefferies said could carry significant strategic value. Jefferies upgraded its outlook on the BAFF/APRIL dual inhibitor, noting the upcoming results from a single ascending dose (SAD) study in healthy volunteers could provide important insight into safety, pharmacokinetics and the company's development roadmap.
Read More
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
Read More
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis.
Read More
Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance
Published: May 12, 2025 by: Benzinga
Sentiment: Positive
Aurinia Pharmaceuticals Inc. AUPH reported first-quarter earnings of 16 cents per share, compared to a loss of 7 cents a year ago. This beat the consensus of 10 cents.
Read More
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2025 Earnings Call Transcript
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Andrea Christopher - Corporate Communications and IR Peter Greenleaf - President and CEO Joe Miller - CFO Greg Keenan - CMO Conference Call Participants Stacy Ku - TD Cowen Maury Raycroft - Jefferies Joseph Schwartz - Leerink Partners Olivia Brayer - Cantor Fitzgerald Sahil Dhingra - RBC Capital Markets David Martin - Bloom Burton Operator Greetings, and welcome to the Aurinia Pharmaceuticals Inc. Q1 2025 Earnings Call. At this time, all participants are in a listen-only mode.
Read More
Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.03 per share a year ago.
Read More
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
Published: May 12, 2025 by: Business Wire
Sentiment: Neutral
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025.
Read More
Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
Published: April 30, 2025 by: Business Wire
Sentiment: Neutral
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Glass Lewis recommends that Aurinia Shareholders vote “FOR” all proposals at 2025 Annual General Meeting.
Read More
ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
Published: April 29, 2025 by: Business Wire
Sentiment: Neutral
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--ISS recommends that Aurinia Shareholders vote “FOR” all proposals at 2025 Annual General Meeting.
Read More
Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth
Published: April 26, 2025 by: Seeking Alpha
Sentiment: Positive
AUPH has seen some management changes, but activist investors demand more despite steady Lupkynis sales growth. The first quarter was strong in terms of sales in 2023 and 2024, and upcoming Q1 '25 earnings represent an opportunity to confirm that trend. AUPH is also expected to report the first clinical data from AUR200 in Q2 '25, which might allow the opportunity for the company to one day grow beyond revenues from Lupkynis.
Read More
Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations
Published: February 27, 2025 by: Benzinga
Sentiment: Neutral
On Thursday, Aurinia Pharmaceuticals Inc AUPH reported fourth-quarter earnings of 1 cent per share, compared to a loss of 19 cents a year ago and the consensus loss of 2 cents.
Read More
Aurinia Pharmaceuticals: There's Still Time For Sales Growth
Published: February 21, 2025 by: Seeking Alpha
Sentiment: Positive
AUPH's Lupkynis showed modest revenue growth from Q2'24 to Q3'24, but limited sales growth going from Q2 to Q3 has been seen previously. Full-year 2024 net product revenue guidance of $210M-$220M appears achievable, with $158.6M already reported and Q4 typically outperforming Q3. Potential competitors in lupus nephritis and even in systemic lupus erythematosus include Roche and Biogen.
Read More
About Aurinia Pharmaceuticals Inc. (AUPH)
- IPO Date 2014-09-03
- Website https://www.auriniapharma.com
- Industry Biotechnology
- CEO Peter S. Greenleaf
- Employees 130